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LIST OF ABBRIVIATIONS 
 
AG Acyl glucuronide  
AGE Advanced glycation end product 
ALT Alanine transaminase 
ARB Angiotensin receptor blocker  
BSO L-Buthionine-(S,R)-sulfoximine 
BUN Blood urea nitrogen 
cDNA Complementary DNA 
CRE Creatinine 
dKF Dansylated lysine-phenylalanine	 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
EDTA Ethylenediamine N,N,N’,N’-tetraacetic acid  
FBS Fetal bovine serum 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase  
GSH Glutathione 
GSSG Disulfide glutathione 
H&E Hematoxylin-eosin  
HEK Human embryonic kidney 
HO-1 Heme oxygenase 1 
hPBMCs Human peripheral blood mononuclear cells 
HPLC High-performance liquid chromatography 
ICAM-1 Intercellular adhesion molecule-1 
IL Interleukin 
KPB  Potassium phosphate buffers 
KO  Knockout 
LC Liquid chromatography 
LTRA Leukotriene receptor antagonist 
Lys-Phe Lysine-phenylalanine 
MAPK Mitogen-activated protein kinase 
MCP-1 Monocyte chemoattractant protein 1 
MDA Malondialdehyde 
MIP-2 Macrophage inflammatory protein-2 
MPO Myeloperoxidase 
mRNA Messenger RNA  
MS Mass spectrometry 
MS/MS Tandem mass spectrometry  
MT Metallothionein 
  
NAD+ Nicotinamide adenine dinucleotide 
NAMPT Nicotinamide phosphoribosyltransferase 
NSAID Nonsteroidal anti-inflammatory drug 
PBS  Phosphate-buffered saline 
RT-PCR  Reverse transcription polymerase chain reaction 
S100A9 S100 calcium-binding protein A9 
SD Standard deviation 
SEM Standard error of mean 
TBARS  Thiobarbituric acid reactive substances 
TNFα  Tumor necrosis factor alpha 
TOTP  Tri-o-tolyl phosphate 
Tris  Tris(hydroxymethyl)aminomethane 
UDP  Uridine 5’-diphosphate 
UDPGA  UDP-Glucuronic acid 
UGT  UDP-Glucuronosyltransferase 
UPLC Ultra-performance liquid chromatography 
ZP  Zomepirac 
ZP-AG  Zomepirac acyl glucuronide 
 





Humans are exposed many drugs and non-drug xenobiotics such as dietary, environmental and 
industrial chemicals which are lipophilic compounds. The conversion of lipophilic compounds 
to more hydrophilic compounds serves as an elimination pathway (Rowland et al., 2013). 
UGTs are phase II enzymes that play important roles in the metabolism of a lot of lipophilic 
endogenous and exogenous compounds (Mackenzie et al., 2005). The glucuronidation is a 
major drug-metabolizing reaction and accounts for approximately 40-75% of xenobiotic 
elimination (Wells et al., 2004). UGTs catalyze the transfer of glucuronic acid from 
UDP-glucuronic acid (UDPGA) to carboxyl groups as well as hydroxyl and amine groups 





Fig. 1. Glucuronidation reaction scheme. 
 
The formations of O- or N-glucuronides by UGTs are considered as a detoxification 
process because these glucuronides are generally neither active nor reactive and are excreted 
rapidly from the body. In contrast, acyl glucuronides (AGs) generated by glucuronidation of a 
carboxylic moiety are unstable and consequently undergo hydrolysis or intramolecular 
rearrangement through the migration of the drug moiety from the 1-O-position to the 2-, 3-, or 
4-positions on the glucuronic acid ring (Smith et al., 1990; Benet et al., 1993; Bailey and 
Dickinson, 2003). It has been reported that AGs can bind covalently to proteins and other 
macromolecules due to their electrophilicity, suggesting that they are associated with the 
immunogenicity and toxicity (Spahn-Langguth and Benet, 1992). In fact, approximately 25% 
of drugs withdrawn from the market because of severe toxicity have been drugs containing a 
R-OH 
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carboxylic acid moiety, such as ibufenac, zomepirac and benoxaprofen (Bailey and Dickinson, 
2003). To date, both direct and immune-mediated toxic pathways have been suggested as 
possible toxic mechanisms of AGs. 
In order to assess the toxicological risks of carboxylic acid-containing drugs, the chemical 
stability and reactivity of AGs have been evaluated. The chemical stability was evaluated by 
the half-lives of AGs in potassium phosphate buffer (KPB). The half-lives of AGs in 
withdrawn drugs were shorter than those in safe drugs. Therefore, this assay is useful to 
predict the risk of toxicity (Sawamura et al., 2010; Jinno et al., 2013). Next, the reactivity of 
AGs was evaluated by the formation of peptide adducts. Lysine-phenylalanine (Lys-Phe), a 
novel trapping agent that forms glycation adducts via a Schiff base, successfully trapped the 
AGs of several drugs. In this assay, a correlation was observed between the formation of a 
peptide adduct and the rearrangement rate of the primary AG of 7 drugs (Wang et al., 2004). In 
addition to chemical instability, mycophenolic acid AG induced tumor necrosis factor alpha 
(TNFα) and interleukin-6 (IL-6) mRNA expression, and diclofenac AG induced interleukin-8 
(IL-8) and monocyte chemoattractant protein 1 (MCP-1) mRNA expression in human 
peripheral blood mononuclear cells (hPBMCs) (Wieland et al., 2000; Miyashita et al., 2014), 
suggesting that the stimulation of immune cells might be involved in adverse reactions of 
carboxylic acid-containing drugs. It remains to be investigated whether AG-peptide adducts 
formation and immunostimulation are related to drug toxicities, although the predictability of 
the half-lives assay for drug toxicity has been evaluated (Sawamura et al., 2010; Jinno et al., 
2013). In Chapter 2, the relationship of the results of half-lives, peptide adducts, and 
immunostimulation assays to the toxic category of carboxylic acid-containing drugs was 
evaluated, and then the usability of the three assays was compared to assess the risk of toxicity 
of AGs in preclinical drug discovery. 
Until now, the chemical stability, the formation of covalent adducts and the immune 
activation have been investigated in vitro. However, the toxicity of AGs has remained 
controversial, because the direct involvement of AGs in toxicity in vivo has not been proved. 
Zomepirac (ZP), a nonsteroidal anti-inflammatory drug, was withdrawn from the market 
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because of their adverse effects such as anaphylaxis and nephrotoxicity (Smith, 1982; Miller et 
al., 1983). ZP is mainly metabolized to acyl glucuronide (ZP-AG) in human (Grindel et al., 
1980; O'Neill et al., 1982). ZP-AG is more physically unstable in phosphate buffer than the 
other AGs of safe drugs such as gemfibrozil, repaglunide and telmisartan (Sawamura et al., 
2010). ZP-AG also covalently modifies dipeptidyl peptidase IV in rat liver homogenates and 
microtubular protein in bovine brain in vitro as well as small peptides such as glutathione 
(GSH) in vivo (Bailey et al., 1998; Wang et al., 2001; Grillo and Hua, 2003). These studies 
suggest that ZP-AG is the cause of the toxicity induced by ZP, but it has not been 
demonstrated whether ZP-AG actually shows toxic effects in vivo. In Chapter 3, the 
relationship between the exposures of ZP and ZP-AG and the severity of ZP-induced toxicity 
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CHAPTER 2 
 
In vitro toxicological evaluation of acyl glucuronides utilizing half-lives, 





Chemical reactivity of AGs is believed to be involved in the toxicity of carboxylic 
acid-containing drugs. Both direct and immune-mediated toxicity have been suggested as 
possible mechanisms of toxicity; however, it remains unclear. In the present study, the assays 
of half-lives, peptide adducts, and immunostimulation were performed to evaluate the 
potential risk of AGs of 21 drugs and analyzed the relationship to the toxic category. AGs of 
all withdrawn drugs tested in this study showed short half-lives and peptide adducts formation, 
but so did those of several safe drugs. In contrast, only AGs of withdrawn and warning drugs 
induced IL-8 in hPBMCs. Using a DNA microarray assay, it was found that zomepirac AG 
induced the mRNAs of 5 genes, including IL-8 in hPBMCs. In addition, withdrawn and 
warning drugs were distinguished from safe drugs by an integrated score of relative mRNA 
expression levels of 5 genes. The immunostimulation assay showed higher sensitivity, 
specificity, and accuracy compared with other methods. In preclinical drug development, the 
evaluation of the reactivity of AGs using half-lives and peptide adducts assays followed by the 
evaluation of immunostimulation by highly reactive AGs using hPBMCs can contribute to 
improved drug safety. 
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INTRODUCTION 
 
Acyl glucuronidation is one of the major metabolic routes of carboxylic acid-containing 
drugs. Glucuronidation is an important phase II metabolic pathway for endogenous and 
exogenous substrates and is generally considered as a detoxification pathway. However, AGs 
are unstable under physiological conditions and consequently undergo hydrolysis or 
intramolecular rearrangement through the migration of the drug moiety from the 1-O-position 
to the 2-, 3-, or 4-positions on the glucuronic acid ring (Smith et al., 1990; Benet et al., 1993; 
Bailey and Dickinson, 2003). Because of their electrophilic nature and capacity to cause 
substitution reactions with nucleophilic groups in proteins or other macromolecules, AGs can 
covalently modify endogenous proteins leading to the adverse toxicity associated with 
carboxylic acid-containing drugs (Faed, 1984; Boelsterli, 2002). Till date, both direct and 
immune- and inflammation-mediated toxic pathways have been suggested as possible toxic 
mechanisms of AGs. Previous studies (Nakayama et al., 2009; Usui et al., 2009) have reported 
that zomepirac and bromfenac, which are carboxylic acid-containing drugs that have been 
withdrawn from the market, showed low covalent binding to proteins in human hepatocytes. In 
addition, the AGs of the widely used drugs naproxen, diclofenac, ketoprofen, and ibuprofen 
did not lead to cytotoxicity or genotoxicity in UGT-transfected human embryonic kidney 293 
(HEK/UGT) cells and human hepatocytes (Koga et al., 2011). In contrast, it has been reported 
that mycophenolic acid AG induced TNFα and IL-6, and diclofenac AG induced IL-8 and 
MCP-1 in leukocytes (Wieland et al., 2000; Miyashita et al., 2014), suggesting that the 
induction of immune modulators could lead to immune- and/or inflammation-related adverse 
drug reactions.  
Several in vitro assay methods to assess the toxicity of AGs have been proposed. The first 
is an evaluation of the half-lives of AGs in KPB. The half-lives of AGs in withdrawn drugs 
were shorter than those in safe drugs. Therefore, this assay is useful to predict the risk of 
toxicity (Sawamura et al., 2010; Jinno et al., 2013). The second method is a Lys-Phe adducts 
assay, wherein Lys-Phe is used as a novel trapping agent that forms glycation adducts via a 
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Schiff base. In this assay, a correlation was observed between the formation of a peptide 
adduct and the rearrangement rate of the primary AG of 7 drugs (Wang et al., 2004). The third 
method is an immunostimulation assay using hPBMCs, wherein cytokines and chemokines, 
such as IL-6 and IL-8, were induced in hPBMCs by treatment with AGs (Wieland et al., 2000; 
Miyashita et al., 2014). Although the predictability of the assay of half-lives for drug toxicity 
has been evaluated (Sawamura et al., 2010; Jinno et al., 2013), the relationship between the 
results of the other two assays and drug toxicity remains to be investigated. The purpose of the 
present study was to evaluate the relationship of the results of assays of half-lives, peptide 
adducts, and immunostimulation to the toxic category of carboxylic acid-containing drugs 
defined by description in drug package inserts, and then to compare the usability of the three 
assays to assess the risk of toxicity of AGs in preclinical drug discovery. The assay of peptide 
adducts was modified by using dansylated Lys-Phe (dKF), peptide-AG adducts of which were 





Chemicals and reagents  
 Oxaprozin, pranoprofen, etodolac, and dKF were prepared in-house by chemosynthesis. 
Probenecid was obtained from Wako Pure Chemical Industries (Osaka, Japan). Diclofenac 
sodium salt, tolmetin sodium salt dihydrate, zomepirac sodium salt, mefenamic acid, 
bumetanide, furosemide, flufenamic acid, meclofenamic acid sodium salt, ibuprofen, and 
repaglinide were obtained from Sigma-Aldrich (St. Louis, MO). Montelukast sodium and 
telmisartan were obtained from Kemprotec (Middlesborough, UK). Gemfibrozil was obtained 
from LKT Laboratories (St. Paul, MN). Naproxen sodium was obtained from Tocris 
Bioscience (Ellisville, MO). Ibufenac, benoxaprofen, piretanide, and AGs of zomepirac, 
benoxaprofen, tolmetin, ibufenac, diclofenac, mefenamic acid, probenecid, naproxen, 
gemfibrozil, furosemide, repaglinide, telmisartan, and ibuprofen were purchased from Toronto 
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Research Chemicals (Ontario, Canada). Pooled human liver microsomes were obtained from 
XenoTech, LLC (Lenexa, KS). The UGT reaction mix solution (250 mM Tris-HCl (pH 7.4), 
40 mM MgCl2, and 0.125 mg/ml alamethicin) was purchased from Corning Gentest (Woburn, 
MA). Characterized hPBMCs (lot no. LP80), uncharacterized hPBMCs (10 individuals), and 
CTL-Test medium were obtained from Cellular Technology (Shaker Heights, OH). TRIzol and 
the High-Capacity cDNA Reverse Transcription Kit were obtained from Life Technologies 
(Carlsbad, CA). TaqMan Universal Master Mix, TaqMan Gene Expression Assays, and Human 
GAPDH Endogenous Control (FAM/MGB probe, non-primer limited) were obtained from 
Applied Biosystems (Darmstadt, Germany). The Human IL-8 ELISA Ready-SET-GO! Kit 
(2nd Generation) was obtained from eBioscience (San Diego, CA). Other chemicals were 
analytical grade or the highest grade commercially available. 
 
Formation of AGs and degradation in KPB in assay of half-lives 
A chemical stability study was performed according to the methods described by Chen et 
al. (2007), with slight modifications. The test compounds were incubated at concentrations of 
500 µM at 37°C for 60 min with pooled human liver microsomes (2.0 mg protein/mL) in 100 
mM Tris-HCl buffer (pH 7.4) containing 10 mM MgCl2, 50 µg/mL alamethicin, and 4 mM 
UDPGA. The volume of each reaction mixture was 300 µL, and the reaction was stopped by 
adding an equal volume of acetonitrile. The reaction-stopped mixture was transferred to new 
reaction tubes and mixed with 4 volumes of 100 mM KPB (pH 7.4). The samples were 
incubated at 37°C and aliquots were removed at 0, 10, 20, 40, 90, 180, and 300 min. The 
reaction was stopped by adding an equal volume of acetonitrile/methanol (90/10) containing 
1% formic acid and the internal standard (0.2 µM niflumic acid). The reaction mixture was 
centrifuged at 3000 rpm at 4°C for 5 min, and then the supernatants were collected and stored 
at −20°C until analysis. 
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Liquid chromatography–tandem mass spectrometry (LC-MS/MS) analysis of AGs in assay 
of half-lives  
To determine half-lives, the 1-O-β-AGs in samples prepared as described above were 
measured by LC-MS/MS. An Acquity system (Waters, Milford, MA) equipped with a Waters 
Acquity UPLC BEH C18 column (1.7 µm, 2.1 mm × 100 mm) and a triple quadrupole mass 
spectrometer (Quattro Premier and Xevo TQ MS; Waters) were used. The AGs were separated 
from other isomers and metabolites using an elution gradient. The mobile phases were 0.1% 
formic acid and acetonitrile. The column was eluted at a flow rate of 0.4 mL/min at 50°C. The 
elution program and the MS/MS condition for detection of AGs are shown in Table 1 and 
Table 2, respectively. 
 
Calculating the half-lives of AGs  
The degradation rate constant (K) of each AG was determined from the LC-MS/MS peak 
area of 1-O-β-AG versus time curve by the linear regression of the semi-logarithmic plot. The 
half-lives (T1/2) were calculated from K by the following equation: 
T1/2 = ln 2/K 
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Table 1.  The elution program of LC method for separating acyl glucuronides. 
Compounds min solvent A % 
solvent B 





Ibuprofen 0.0 98 2 none  Diclofenac 0.0 98 2 none 
Gemfibrozil 0.5 98 2 none  Etodolac 0.5 98 2 none 
 6.0 30 70 linear   1.5 60 40 linear 
 6.1 98 2 none   4.5 60 40 none 
 8.0 98 2 none   5.5 5 95 linear 
       6.0 5 95 none 
       6.1 98 2 none 
       8.0 98 2 none 
Compounds min solvent A % 
solvent B 





Oxaprozin 0.0 98 2 none  Repaglinide 0.0 98 2 none 
 0.5 98 2 none  Bumetanide 0.5 98 2 none 
 1.5 63 37 linear   1.5 65 35 linear 
 4.5 63 37 none   4.5 65 35 none 
 5.5 5 95 linear   5.5 5 95 linear 
 6.0 5 95 none   6.0 5 95 none 
 6.1 98 2 none   6.1 98 2 none 
 8.0 98 2 none   8.0 98 2 none 
Compounds min solvent A % 
solvent B 





Ketoprofen 0.0 98 2 none  Piretanide 0.0 98 2 none 
Ibufenac 0.5 98 2 none   0.5 98 2 none 
 1.5 70 30 linear   1.5 70 30 linear 
 4.5 70 30 none   4.5 70 30 none 
 5.5 20 80 linear   5.5 5 95 linear 
 6.0 20 80 none   6.0 5 95 none 
 6.1 98 2 none   6.1 98 2 none 
  8.0 98 2 none     8.0 98 2 none 
Compounds min solvent A % 
solvent B 





Pranoprofen 0.0 98 2 none  Others 0.0 98 2 none 
 0.5 98 2 none   0.5 98 2 none 
 1.5 75 25 linear   5.0 2 98 linear 
 4.5 75 25 none   6.0 2 98 none 
 5.5 5 95 linear   6.1 98 2 none 
 6.0 5 95 none   8.0 98 2 none 
 6.1 98 2 none       
  8.0 98 2 none             
Solvent A: 0.1% formic acid, solvent B: acetonitrile.       
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Table 2.  The MS/MS condition for acyl glucuronides detection. 
Compounds   Ion Mode Q1 Q3   Compounds   Ion Mode Q1 Q3 
Niflumic acid I.S. ES+ 283.1 245.1            
Flufenamic acid UC ES+ 282.1 167.0  Naproxen UC ES+ 231.1 185.1 
 AG ES+ 282.1 167.0   AG ES+ 231.1 185.1 
Gemfibrozil UC ES- 249.1 120.9  Montelukast UC ES+ 586.2 422.2 
  AG ES- 425.0 249.0    AG ES+ 586.2 422.2 
Meclofenamic 
acid UC ES+ 296.1 243.1  Probenecid UC ES+ 286.1 121.1 
  AG ES+ 472.0 296.0    AG ES+ 462.1 286.1 
Repaglinide UC ES+ 453.3 230.2  Dicｌofenac UC ES+ 296.1 214.2 
 AG ES+ 629.3 453.3   AG ES+ 296.1 214.2 
Telmisartan UC ES+ 515.2 276.3  Mefenamic acid UC ES+ 242.1 180.1 
  AG ES+ 691.2 515.2    AG ES+ 418.0 242.0 
Furosemide UC ES+ 331.0 81.0  Tolmetin UC ES+ 258.1 119.1 
 AG ES+ 331.0 81.0   AG ES+ 258.1 119.1 
Ibuprofen UC ES- 205.0 161.0  Benoxaprofen UC ES+ 302.1 256.1 
  AG ES- 381.0 205.0    AG ES+ 302.1 256.1 
Ibufenac UC ES+ 193.1 147.1  Pranoprofen UC ES+ 256.1 210.2 
 AG ES+ 193.1 147.1   AG ES+ 256.1 210.2 
Zomepirac UC ES+ 292.1 110.9  Etodolac UC ES+ 288.2 171.9 
  AG ES+ 292.1 110.9    AG ES+ 464.2 288.2 
Bumetanide UC ES+ 365.2 240.2  Oxaprozin UC ES+ 294.1 102.8 
  AG ES+ 541.2 365.2    AG ES+ 294.1 102.8 
Piretanide UC ES+ 363.2 282.2        
  AG ES+ 539.2 282.2             
UC, unchanged; AG, acyl glucuronide         
Q1 of acyl glucuronide is Q1 of unchanged drug or Q1 of  unchanged drug + 176 Da (glucuronic acid moiety).  
Q3 of acyl glucuronide is Q1 of unchanged drug or Q3 of  unchanged drug.     
Formation of AG-dKF adducts  
The test compounds were incubated at concentrations of 500 µM with pooled human liver 
microsomes (2.0 mg protein/mL) in 88 mM KPB (pH 7.4) containing 8 mM MgCl2, 25 µg/mL 
alamethicin, and 4 mM UDPGA at 37°C for 60 min. The volume of the mixture was 500 µL, 
and the reaction was stopped by adding 1 mL of ice-cold acetonitrile, followed by 
centrifugation at 14,000 rpm at 4°C for 5 min. The supernatant (1.4 mL) was transferred into 
another test tube, evaporated to dryness under a N2 stream at 40°C, and resuspended in 500 µL 
of acetonitrile/KPB (15/85) containing 10 mM dKF. After 3 h incubation at 37°C, the mixture 
was evaporated to dryness under a N2 stream at 40°C, resuspended in 500 µL of 
acetonitrile/water (50/50), and filtrated (0.2-µm filter) by centrifugation at 4,500 g at 4°C for 
10 min. The AG-dKF adducts were analyzed by LC-mass spectrometry (MS) and fluorescence 
as follows. 
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LC-MS analysis of AG-dKF adducts 
Samples prepared as described above were subjected to LC-MS. An Acquity system 
(Waters) equipped with a Waters Acquity UPLC HSS T3 column (1.8 µm, 2.1 mm × 50 mm) 
was used. Mobile phases were 0.1% formic acid (solvent A) and 90% acetonitrile containing 
0.1% formic acid (solvent B). The column was eluted at a flow rate of 0.6 mL/min at 40°C. 
Conditions for elution were as follows: 20% solvent B (0–1 min), 20%–50% B (1–7 min), 
50%–90% B (7–13 min), 90% B (13–14 min), and 20% B (14.1–15.5 min). The dKF adducts 
were detected by fluorescence (excitation 340 nm, emission 525 nm) using a fluorescence 
detector (2475 Multi λ Fluorescence Detector; Waters) and mass spectrometry using a hybrid 
triple quadrupole/linear ion trap mass spectrometer (4000 QTRAP; AB Sciex, Framingham, 
MA). Parameters for mass spectrometers were as follows: ion mode, positive-electrospray 
ionization (enhanced MS scan mode); collisionally activated dissociation, high; curtain gas, 30 
psi; ion source gas 1, 40 psi; ion source gas 2, 80 psi; ion source voltage, 5000 V; source 
temperature, 500°C; full scan mass range, 200–900 (doubly charged ion). The dKF adducts 
were formed via acylation or glycation. Acylation adducts and glycation adducts were detected 
at m/z M/2 + 297 and M/2 + 385, respectively, ([M + 2H]2+; M: the molecular weight of 
unchanged drug). The schematics of chemical mechanisms of acylation and glycation and 
chemical structures of peptide adducts are shown in Figure 2. 
 
  



























Fig. 2. The schematics of chemical mechanisms of acylation and glycation (A) and chemical structures of 
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Cell culture in immunostimulation assay  
The hPBMCs were maintained at 37°C under an atmosphere of 5% CO2. For the assay, the 
hPBMCs were seeded at densities of 3 × 105 cells/well in a 24-well plate with medium 
containing 100 µM AG and then incubated at 37°C for 24 h. The AGs were dissolved in 
dimethyl sulfoxide (DMSO) containing 1% formic acid at 50 mM concentration, and the final 
concentration of DMSO in the culture medium was 0.2% in all of the experiments. 
 
Real-time reverse transcription polymerase chain reaction (RT-PCR) 
Total RNA was extracted from the cultured cells using TRIzol (Life Technologies) 
according to the manufacturer’s protocol. The reverse transcription was performed with the 
High-Capacity cDNA Reverse Transcription Kit (Life Technologies) according to the 
manufacturer’s protocol. Two microliters of cDNA was used for quantitative real-time 
RT-PCR, which was performed in the 7900HT Fast Real-Time PCR System (Applied 
Biosystems) capable of fluorescence using TaqMan Universal Master Mix (Applied 
Biosystems). Gene-specific oligonucleotide primers and probes for human cluster of 
differentiation 69 (CD69; assay ID: Hs00934033_m1), chemokine (C-X3-C motif) receptor 1 
(CXCR1; assay ID: Hs01922583_s1), interferon gamma (IFNγ; assayID: Hs00989291_m1), 
IL-1α (assay ID: Hs00174092_m1), IL-6 (assay ID: Hs00985639_m1), IL-8 (assay ID: 
Hs00174103_m1), lymphocyte cytosolic protein 2 (LCP2; assay ID: Hs01092638_m1), 
microsomal glutathione S-transferase 1 (MGST1; assay ID: Hs00220393_m1), metallothionein 
(MT) 2A (assay ID: Hs02379661_g1), and nicotinamide phosphoribosyltransferase (NAMPT; 
assay ID: Hs00237184_m1) were obtained as TaqMan Gene Expression Assays (Applied 
Biosystems). The reaction mixture contained 10 µL TaqMan Universal Master Mix and 1 µL 
of the specific primer in a final volume of 20 µL. The PCR conditions were as follows: after 
an initial polymerase activation at 95°C for 20 seconds, the amplification was performed 
through 40 cycles of either denaturation at 95°C for 1 second or annealing and extension at 
60°C for 20 seconds. To normalize the RNA loading and PCR variations, the signals of the 
targets were normalized to those of human GAPDH mRNA. 
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Enzyme-linked immunosorbent assay (ELISA) 
The levels of the inflammatory chemokine IL-8 in cultured medium were measured using 
the Human IL-8 ELISA Ready-SET-GO! Kit (eBioscience), according to the manufacturer’s 
instructions. 
 
DNA microarray analysis 
Total RNA was extracted from hPBMCs treated with 100 µM zomepirac AG, tolmetin AG 
(positive control), or ibuprofen AG (negative control) for 24 h using TRIzol. The total RNA 
concentration was calculated with an OD260 using a NanoDrop (ND-1000), and the 
OD260/280 was confirmed to be 1.8 or more. The integrity of total RNA was examined with a 
2100 BioAnalyzer (Agilent Technologies), and its RNA Integrity Number (RIN) value was 
confirmed to be 6 or more. The cDNA synthesis, biotin labeling, purification, fragmentation, 
hybridization, and scanning of GeneChip arrays were performed according to the GeneChip 3′ 
IVT Express Kit user manual (Affymetrix). The biotinylated and fragmented complementary 
RNA was hybridized on the GeneChip Human Genome U133 Plus 2.0 Array (38,500 genes). 
After the hybridization, washing and fluorescence staining were performed using a Fluidics 
station 450 (Affymetrix). Next, the arrays were scanned using the GeneChip Scanner 3000, 
and the scanned images were analyzed using the Expression Console Ver.1.1 (Affymetrix). 




The statistical analysis of multiple groups was performed using one-way ANOVA with 
Dunnett’s post hoc test to determine the significance of differences between individual groups. 
Comparisons between two groups were carried out using two-tailed Student’s t tests. A value 
of P < 0.05 was considered statistically significant. 
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RESULTS 
 
Half-lives of AGs in KPB 
In the present study, the 21 carboxylic acid-containing drugs shown in Table 3 were 
categorized into three groups on the basis of severe adverse drug reactions as follows. The 4 
drugs categorized as “withdrawn” included drugs withdrawn from the market because of their 
toxicity, with potential to cause hepatotoxicity and anaphylaxis. The 3 drugs with a warning 
about fulminant hepatitis in drug package inserts in Japan or the United States or in the 
summary of product characteristics in Europe were categorized as “warning.” The other 14 
drugs with no warnings in drug package inserts were categorized as “safe” drugs. First, the 
half-lives of the 21 AGs were evaluated. The half-lives of AGs of the all withdrawn drugs 
were shorter than 2 h, and the AG of diclofenac, which was categorized as a warning drug, 
also had a short half-life. However, the half-lives of AGs of the other 2 warning drugs were 
longer than 2 h, and the half-lives of AGs of several drugs categorized as safe, including 
probenecid, bumetanide, piretanide, oxaprozin, ibuprofen, and pranoprofen, were shorter than 
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Category Drugs Class Dose 
      mg/man/day 
Withdrawn Zomepirac NSAID 600   
 Benoxaprofen NSAID 600  
 Tolmetin NSAID 1800  
  Ibufenac NSAID 4000   
Warning Diclofenac NSAID 200  
 Mefenamic acid NSAID 1500  
  Montelukast LTRA 10  
Safe Probenecid Uricosuric agent 1000   
 Naproxen NSAID 600  
 Gemfibrozil Lipid regulator 1200  
 Furosemide Loop diuretic  80  
 Repaglinide Hypoglycemic agent 16  
 Telmisartan ARB 80  
 Ibuprofen NSAID 3200  
 Bumetanide Loop diuretic  2  
 Piretanide Loop diuretic  12  
 Oxaprozin NSAID 600  
 Pranoprofen NSAID 225  
 Flufenamic acid NSAID 750  
 Meclofenamic acid NSAID 400  
  Etodolac NSAID 400   
NSAID: Non-steroidal anti-inflammatory drug   
LTRA: Leukotriene receptor antagonist   
ARB: Angiotensin receptor blocker   
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Formation of dKF adducts of AGs 
The production of dKF adducts was assessed by fluorescence and LC-MS. When 
diclofenac was incubated with dKF as a positive control, an acylation adduct and multiple 
glycation adducts were detected by fluorescence and MS (Fig. 3). The multiple glycation 
adducts of dicolofenac detected in this assay would be isomers of AGs formed via 
intramolecular rearrangement. Such dKF adducts were not detected in the absence of 
diclofenac or UDPGA. As shown in Table 4, AGs of all withdrawn drugs formed glycation 
adducts but not acylation adducts. For some of the safe drugs with short half-lives, acylation 
and/or glycation adducts were detected, although the drugs that formed neither acylation nor 
Category Drugs Half-lives dKF dKF 
    h acylation adduct glycation adduct 
Withdrawn Zomepirac 0.5  - + 
 Benoxaprofen 1.2  - + 
 Tolmetin 0.4  - + 
  Ibufenac 1.0   - + 
Warning Diclofenac 0.7  + ++ 
 Mefenamic acid >15.0  - - 
  Montelukast 9.3   - - 
Safe Probenecid 0.4   - + 
 Naproxen 3.1  + - 
 Gemfibrozil >15.0  - - 
 Furosemide 3.8  - + 
 Repaglinide 11.5  + - 
 Telmisartan >15.0  - - 
 Ibuprofen 1.8  + - 
 Bumetanide 0.3  + ++ 
 Piretanide 1.0  + ++ 
 Oxaprozin 1.1  +  
 Pranoprofen 1.9  - - 
 Flufenamic acid 7.5  ++ ++ 
 Meclofenamic acid >15.0  + + 
  Etodolac >15.0   - - 
++: Detected adducts more than 100 pmol/h/mg  
+: Detected adducts less than 100 pmol/h/mg  
-: Not detected.     
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glycation adducts had long half-lives, except for pranoprofen. On the whole, the formation of 
glycation adducts was better correlated with toxicological category than the formation of 
acylation adducts (Table 4). These results suggest that glycated proteins rather than acylated 
proteins are involved in the toxicity of AGs. However, similar to the assay of half-lives, the 




























Fig. 3. Fluorescence (A) and ion chromatograms (B, C) from LC-MS analysis of the dKF adducts of 
diclofenac AG. (B) Extracted ion current (XIC) chromatograms of the acylation adducts of diclofenac AG at m/z 
445 ([M + 2H]2+). (C) XIC chromatograms of the glycation adducts of diclofenac AG at m/z 533 ([M + 2H]2+). 
LC-MS conditions were as described in Experimental Procedures. 
A
B
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IL-8 mRNA induction in hPBMCs by AGs 
A previous study demonstrated that exposure of hPBMCs to diclofenac AG resulted in an 
increase in the expression of IL-8 mRNA, suggesting that AGs could induce immune and 
inflammation responses (Miyashita et al., 2014). To examine whether the increase in IL-8 in 
hPBMCs is associated with the toxic category, the induction of IL-8 mRNA expression after 
treatment with AGs was evaluated for 4 withdrawn drugs, 2 warning drugs, and 7 safe drugs. 
The expression of IL-8 mRNA was significantly increased by AGs of all withdrawn drugs and 
the warning drugs mefenamic acid and diclofenac but not by AGs of any of the safe drugs 
(Fig. 4A). Moreover, IL-8 protein release was significantly increased by the treatment with 
AGs of several withdrawn drugs (Fig. 4B). These results suggest that immune and 
inflammatory responses are involved in the toxicity of AGs, and the induction of IL-8 mRNA 





















Fig. 4. Effects of AGs on the mRNA expression levels (A) and the protein release (B) of IL-8 in hPBMCs. 
hPBMCs were treated with 14 AGs (100 µM), or vehicle (0.2% DMSO) for 24 h. The IL-8 mRNA levels in 
hPBMCs and released protein in cultured medium were measured by real-time RT-PCR and ELISA, respectively, 
and the IL-8 mRNA levels were normalized with GAPDH mRNA as described in Experimental Procedures. The 
data represent relative changes to vehicle control and are the means ± SD (n = 3). *P < 0.01 as compared with 
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Interindividual differences among hPBMCs for IL-8 mRNA induction by AGs 
For the construction of screening protocols, it is important to examine interindividual 
differences in responses among hPBMCs. IL-8 mRNA induction by zomepirac AG in 
hPBMCs from 11 different individuals was measured (Fig. 5). The upregulation of IL-8 
mRNA by zomepirac AG was observed in hPBMCs from all 11 individuals; however, there 
was no upregulation by ibuprofen AG. There was an approximately 3.5-fold interindividual 
variability in IL-8 mRNA induction. Therefore, the immunostimulation by zomepirac AG 



















Fig. 5. Effects of zomepirac AG and ibuprofen AG on the mRNA expression levels of IL-8 in hPBMCs from 
11 individuals. hPBMCs were treated with zomepirac AG, ibuprofen AG (100 µM), or vehicle (0.2% DMSO) for 
24 h. The expression level of IL-8 mRNA was measured by real-time RT-PCR and normalized with that of 
GAPDH mRNA as described in Experimental Procedures. The data represent the means ± SD (n = 3). 
 
Toxicological assessment by changes in multiple gene expression 
A DNA microarray analysis was performed to search for biomarkers other than IL-8 for 
toxicity of AGs. RNA samples from hPBMCs treated with AGs of zomepirac, tolmetin, or 
ibuprofen were analyzed. There were 201 genes upregulated more than 1.5-fold by AGs of 
both zomepirac and tolmetin that were not or were less upregulated by ibuprofen AG. Among 
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among the MT isoforms), and NAMPT, all of which are related to immune response or 
toxicity, were selected in addition to IL-8 (Table 5). The real-time RT-PCR analysis of mRNA 
of the 10 selected genes showed significant induction (more than 2-fold compared to vehicle 
control) of IL-8, IL-1α, IL-6, MT2A, and NAMPT mRNA by zomepirac AG (Fig. 6). Further 
evaluation was carried out using a total sum score, which was defined as an integrated score of 
the relative expression levels of mRNA of these 5 genes in hPBMCs treated with AGs of other 
drugs (4 withdrawn drugs, 2 warning drugs, and 7 safe drugs). The total sum scores of gene 
expression for AGs of all withdrawn and warning drugs were higher than 10, which represents 
a greater than 2-fold induction compared with vehicle treatment. In contrast, the total sum 
scores for AGs of all safe drugs were lower than 10. Therefore, this method could distinguish 
withdrawn and warning drugs from safe drugs when a total sum score of 10 was used as a 
cut-off value for safe drugs (Fig. 7). 
 
 Table 5.  Summary of immune-associated or toxicity-associated genes that showed changed expression 
after exposure to AGs of zomepirac, tolmetin, or ibuprofen. 
 
  
Gene symbol Gene title Fold changes 
  AGs 
    Zomepirac Tolmetin  Ibuprofen 
CD69 CD69 molecule 2.31  1.52  1.23  
CX3CR1 chemokine (C-X3-C motif) receptor 1 1.98  1.62  1.26  
IFNG interferon, gamma 1.59  1.57  1.22  
IL-1A interleukin 1, alpha 17.39  3.33  2.54  
IL-6 interleukin 6 (interferon, beta 2) 4.34  1.63  1.43  
IL-8 interleukin 8 4.53  1.91  1.25  
LCP2 lymphocyte cytosolic protein 2 2.15  1.52  1.24  
MGST1 microsomal glutathione S-transferase 1 1.82  1.74  0.94  
MT1E metallothionein 1E 4.15  2.34  1.24  
MT1F metallothionein 1F 3.29  2.06  1.11  
MT1G metallothionein 1G 2.95  1.67  1.14  
MT1H metallothionein 1H 3.81  2.15  1.09  
MT1X metallothionein 1X 4.07  2.93  1.36  
MT2A metallothionein 2A 4.94  3.12  1.45  
NAMPT nicotinamide phosphoribosyltransferase 3.66   1.88   1.09   



















Fig. 6. Effects of zomepirac AG on the mRNA expression levels of IL-8, CD69, CXCR1, INFγ, IL-1α, IL-6, 
LCP2, MGST1, MT2A, and NAMPT in hPBMCs. hPBMCs were treated with zomepirac AG (100 µM), or 
vehicle (0.2% DMSO) for 24 h. The expression level of each mRNA was measured by real-time RT-PCR and 
normalized with that of GAPDH mRNA as described in Experimental Procedures. The data represent the means 



















Fig. 7. Total sum score of gene expression level of 14 drugs. The total sum score of gene expression level was 
defined as an integrated score of the relative expression levels of IL-8, IL-1α, IL-6, MT2A, and NAMPT mRNA 
in hPBMCs. The expression level of each mRNA was measured by real-time RT-PCR and normalized with that 
of GAPDH mRNA as described in Experimental Procedures. Red indicates withdrawn drugs, orange indicates 
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Comparison of half-lives, dKF adduct formation, and immunostimulation assay for 
toxicological assessment of AGs 
The 4 withdrawn drugs were identified as toxic by all 3 assays (Table 6). However, among 
the safe drugs, probenecid, bumetanide, and piretanide were identified as toxic by the assays 
of half-lives and dKF adduct formation. Oxaprozin, ibuprofen, and pranoprofen were 
identified as toxic by the assay of half-lives, and furosemide, flufenamic acid, and 
meclofenamic acid were identified as toxic in the dKF adduct formation assay. In contrast, 
AGs of all 7 safe drugs examined using the immunostimulation assay were identified as 
nontoxic. To assess the feasibility of these assays, specificity, sensitivity, and accuracy were 
calculated. For the assays of half-lives and dKF adduct formation, the specificity (57%) was 
less than the sensitivity (71%), i.e., false-positives were more frequent than false-negatives. 
Interestingly, there were no false-positives or false-negatives in the immunostimulation assay. 
Therefore, in the present study, the immunostimulation assay was the most accurate for 
toxicological assessment (Table 7). 
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Table 6.  Comparison of half-lives, formation of dKF adducts, and immunostimulation assays for 





























Category Drugs Half-lives dKF Total sum score 
      glycation adduct  
Withdrawn Zomepirac + + + 
 Benoxaprofen + + + 
 Tolmetin + + + 
  Ibufenac + + + 
Warning Diclofenac + ++ + 
 Mefenamic acid - - + 
  Montelukast - - NA 
Safe Probenecid + + - 
 Naproxen - - - 
 Gemfibrozil - - - 
 Furosemide - + - 
 Repaglinide - - - 
 Telmisartan - - - 
 Ibuprofen + - - 
 Bumetanide + ++ NT 
 Piretanide + ++ NT 
 Oxaprozin +  NT 
 Pranoprofen + - NT 
 Flufenamic acid - ++ NT 
 Meclofenamic acid - + NT 
  Etodolac - - NT 
++: Detected glycation adducts more than 100 pmol/h/mg 
+: Half-life < 2h or detected glycation adducts less than 100 pmol/h/mg or total sum score > 10. 
-: Half-life ≧ 2h or not detected glycation adducts or total sum score ≦ 10. 
NT: Not tested because authentic AGs were not commercially available. 
NA: Not available by a decrease of GAPDH mRNA expression. 
  + - Sensitivity (%) Specificity (%) Accuracy (%) 
Half-lives assay           
    Withdrawn and warning 5 2 
71 57 62 
    Safe 6 8 
dKF adducts formation assay         
    Withdrawn and warning 5 2 
71 57 62 
    Safe 6 8 
Immunostimulation assay           
    Withdrawn and warning 6 0 100 100 100 
    Safe 0 7 
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DISCUSSION 
 
The AGs of drugs are generally unstable and are believed to be involved in drug-induced 
toxicity via the formation of covalent adducts to endogenous proteins. In the process of drug 
discovery, it is important to predict and avoid the toxicity of AGs of new chemical entities, to 
reduce the need to withdraw drugs from the market, and to increase safety in clinical trials. 
Although there is increasing evidence that AGs form drug–protein adducts via their chemical 
reactivity (Grubb et al., 1993; Wang et al., 2001; Horng and Benet, 2013), cytotoxicity and 
genotoxicity of AGs have not been observed in the in vitro assays, suggesting that the toxicity 
of AGs could be mediated by immune-related and/or inflammation-related responses (Koga et 
al., 2011). However, the toxicity of AGs has remained controversial. Therefore, in the present 
study, the aspects of the chemical instability, reactivity, and immunostimulation potential of 
AGs in a range of drugs were evaluated using assays of half-lives, dKF adduct formation, and 
immunostimulation, respectively. 
The evaluation of half-life in KPB has been used to assess the chemical instability of AGs 
(Chen et al., 2007; Sawamura et al., 2010; Jinno et al., 2013). Similar to the results of previous 
studies, in the present study, the half-lives of withdrawn drugs tended to be short (less than 2 
h). However, of particular note is the finding that AGs of some drugs categorized as safe 
(bumetanide, piretanide, oxaprozin, ibuprofen, and pranoprofen) also had short half-lives, 
indicating chemical instability. Therefore, this method may produce false-positive results. 
Half-lives in KPB reflect not only the degradation of 1-O-β-AG via hydrolysis but also the 
intramolecular rearrangement. It has been reported that the percentage of AG rearrangement of 
ibuprofen is less than that of zomepirac and tolmetin (Wang et al., 2004). Therefore, the 
unstable AGs of safe drugs, such as ibuprofen, may be mainly degraded via hydrolysis to 
aglycones and less so via intramolecular rearrangement and would have low reactivity. In 
contrast, it was suggested that the unstable AGs of withdrawn or warning drugs, such as 
zomepirac or diclofenac, were less hydrolyzed but highly formed intramolecular 
rearrangement resulting in formation of glycation adducts. 
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Next, the formation of peptide adducts using dKF was examined to evaluate the chemical 
reactivity of AGs with proteins. dKF is a novel trapping agent rendered detectable by 
fluorescence by dansylation of KF, which forms adducts with AG. Glycation adducts were 
detected in all withdrawn drugs tested in the present study, whereas acylation adducts were 
not. Consequently, the formation of glycation adducts rather than acylation adducts was 
suggested to correlate with toxicity. Unlike acylation adducts, glycated proteins are formed 
through Schiff bases and Amadori rearrangement and generate advanced glycation end 
products (AGEs). AGEs contribute to various diseases, including the complications of 
diabetes, arterial sclerosis, and liver disease, mediated by immune mechanisms (Ramasamy et 
al., 2005; Takeuchi et al., 2014). AGEs originating from glycated proteins may be partially 
involved in the toxicity of AGs. Glycation adducts were detected not only in withdrawn drugs 
but also in several safe drugs (bumetanide, piretanide, furosemide, flufenamic acid, and 
meclofenamic acid). Therefore, as for the half-lives assay, the evaluation of peptide adducts 
has the potential to produce false-positive results and does not accurately predict the toxicity 
of AGs. 
In our previous study, it was found that immune- and inflammation-related genes, such as 
IL-8 and MCP-1, in hPBMCs were up-regulated by diclofenac AG (Miyashita et al., 2014). To 
investigate the immunotoxicity of AGs and to establish a novel method with high prediction 
accuracy, we performed an immunostimulation assay using hPBMCs. Consistent with our 
previous study (Miyashita et al., 2014), IL-8 mRNA induction in hPBMCs by diclofenac AG 
was confirmed, and significant induction of IL-8 by AGs of all withdrawn drugs was 
identified. Notably, the AGs of safe drugs did not induce IL-8 mRNA, showing accurate 
correlation with the toxic category. It was demonstrated that the parent compounds zomepirac 
and tolmetin did not increase the expression of IL-8 mRNA (data not shown). IL-8 is a 
chemokine that exhibits multiple effects on neutrophils, including induction of lysosomal 
enzyme release, increase in the expression of adhesion molecules, and rapid infiltration 
(Leonard et al., 1991; Baggiolini et al., 1994). In the previous report, dicofenac AG suggested 
to be involved in liver injury because there was good correlation between the concentration of 
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liver diclofenac AG and plasma alanine transaminase (ALT) levels in transporter KO mice 
(Lagas et al., 2010). Moreover, in mice in vivo study, the mRNA expression of macrophage 
inflammatory protein (MIP)-2 that is mouse orthologue of human IL-8 is dramatically induced 
in correlation with the extent of liver injury after diclofenac administration (Yano et al., 2014). 
Taken together, it is suggested that the toxicity caused by diclofenac AG is mediated via IL-8 
induction. Furthermore, in assessment of allergen potency, IL-8 release from THP-1 cells have 
a high correlation with the local lymph node assay, animal model of evaluating skin 
sensitization, could be a useful marker (Mitjans et al., 2010). Therefore, IL-8 is suggested to 
be a potentially good marker for assessing the toxicity caused by AG. Moreover, the induction 
of IL-8 mRNA by zomepirac AG was also observed in hPBMCs from 11 different individuals, 
and interindividual differences were not marked (less than 4-fold). The upregulation of IL-8 
mRNA by zomepirac AG was observed in hPBMCs from all 11 individuals, and 
interindividual differences appeared to be not marked. Thus, only the induction of IL-8 could 
not explain the idiosyncrasy. Idiosyncratic toxicity is thought to be caused by not a single 
factor but rather the complex of multiple factors. The factors include not only the compound 
potential but also the recipient’s potential (e.g. age, sex, food, surrounding environment, 
genetic polymorphism etc.). The induction of IL-8 is one of the risk factors leading to 
idiosyncratic toxicity, and IL-1α, IL-6, MT2A, and NAMPT are newly found to potentially be 
the risk factors in our study. It is important to totally assess multiple factors, and selecting low 
potential compounds such as ibuprofen in drug discovery might result in reducing the risk of 
idiosyncratic drug toxicity. 
To find novel biomarkers other than IL-8 to improve risk prediction, a DNA microarray 
assay was conducted using cDNA samples from hPBMCs exposed to AGs of zomepirac, 
tolmetin, or ibuprofen. Among the genes that were upregulated only by the treatment with AGs 
of withdrawn drugs (zomepirac and tolmetin), 10 immune- or toxicity-associated genes were 
selected. The mRNA of IL-8, IL-1α, IL-6, MT2A, and NAMPT was highly induced when the 
genes were individually analyzed by real-time RT-PCR. Based on a previous report (Yano et 
al., 2014) that assessed the risk of hepatotoxic and nonhepatotoxic drugs using an integrated 
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score of relative expression levels of several immune-associated genes, the 5 genes described 
above were applied as biomarkers to predict the toxicity of AGs. An integrated score of 
relative expression levels of selected genes enabled the discrimination of withdrawn drugs 
from safe drugs based on a cut-off score of 10, which represents a greater than 2-fold 
induction relative to vehicle controls. Furthermore, this evaluation method predicted toxicity 
with higher sensitivity, specificity, and accuracy than the other two methods. 
IL-1α is a proinflammatory cytokine, constitutively expressed in gastrointestinal tract, 
lung, liver, kidney, endothelial cells, and astrocytes. It is a key mediator of autoimmune and 
inflammatory diseases (Garlanda et al., 2013). IL-6 is a prototypical cytokine produced by 
many different types of lymphoid and nonlymphoid cells, such as T cells, B cells, monocytes, 
fibroblasts, keratinocytes, and endothelial cells. It not only induces the differentiation of B 
cells and T cells but also stimulates hepatocytes to produce acute-phase proteins (Hirano and 
Kishimoto, 1989; Tanaka and Kishimoto, 2014). NAMPT is the rate-limiting enzyme in 
nicotinamide adenine dinucleotide (NAD+) biosynthesis and is implicated in the maturation of 
B cell precursors. This gene is up-regulated in neutrophil activation and stimulated monocytes 
(Skokowa et al., 2009). The induction of IL-8, IL-1α, IL-6, and NAMPT suggested that AGs 
of withdrawn drugs led to immune response activation, such as cytokines release, 
differentiation of immune cells, neutrophil infiltration, and inflammation. MTs plays important 
roles in scavenging reactive oxygen species and in heavy metal detoxification (Sato and 
Kondoh, 2002), and MT2A is one of the major isoforms of MT in humans (Haynes et al., 
2013). MTs are induced not only by heavy metals but also by reactive oxygen species and 
cytokines such as IL-6 (Itoh et al., 1996). Therefore, in addition to immune-associated genes, 
MTs were also induced by AGs of withdrawn drugs. 
The mechanisms underlying the effects of AGs on the immune system remain unclear. 
Recently, it was shown that the p38 mitogen-activated protein kinase (MAPK) pathway was 
involved in the increase in the expression levels of IL-8 mRNA in hPBMCs induced by AGs 
(Miyashita et al., 2014). In the DNA microarray analysis, other immune related factors were 
upregulated in addition to IL-8. Along with IL-8, the production of IL-6 in hPBMCs induced 
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by the stimulation of ribotoxin was mediated through p38 MAPK activation (Islam et al., 
2006). Moreover, IL-1α is involved in the induction of IL-8 by osmotic stress in hPBMCs via 
the phosphorylation of p38 MAPK (Shapiro and Dinarello, 1995). The expression of both MT 
and NAMPT were increased by IL-6 during immune activation in mice (Itoh et al., 1996; 
Nowell et al., 2006). Taken together, it was hypothesized that IL-1α, which acts in the 
acute-phase response, induces IL-6 and IL-8 via the p38 MAPK pathway and that MT and 
NAMPT would be upregulated by cytokines such as IL-6. 
In the present study, 3 different assays were compared to assess the risk of carboxylic 
acid-containing drugs. All methods accurately identified the high-risk withdrawn drugs; 
however, the immunostimulation assay was superior in terms of negative predictive value. 
This finding suggests that high reactivity does not always have the potential to activate an 
immune response. The evaluation of immune responses using hPBMCs had the highest 
accuracy in the present study, but this method requires authentic AG standards. Therefore, this 
assay is appropriate in the late stages of preclinical drug development. 
In conclusion, 3 assay systems were compared to assess the toxicity risk of AGs. The 
results indicated that the immunostimulation assay is more suitable to evaluate toxicity risk 
than the assay of half-lives or the formation of peptide adducts. However, the latter 2 assays 
are more convenient because there is no requirement for authentic AG standards. It is proposed 
that each assay system can be adopted, depending on the stage in drug development. In early 
stage, new chemical entities are evaluated using high-throughput assays of half-lives and 
peptide adducts in the early stages. If the drugs are judged as toxic in both assays, the 
immunostimulation assay using authentic AGs should be conducted to accurately determine 
toxicity prior to clinical trials. 
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CHAPTER 3 
 




Glucuronidation, an important phase II metabolic route, is generally considered as a 
detoxification pathway. However, AGs have been implicated in the toxicity of drugs 
containing carboxyl acid moiety due to their electrophilic reactivity. Zomepirac (ZP) was 
withdrawn from the market because of their adverse effects such as renal toxicity. ZP is mainly 
metabolized to acyl glucuronide (ZP-AG) by UGT. However, the responsibility of ZP-AG to 
renal toxicity has never been proven. In this study, ZP-induced kidney injury mouse model 
was established by pretreatment with tri-o-tolyl phosphate (TOTP), a non-selective esterase 
inhibitor, and L-buthionine-(S,R)-sulfoximine (BSO), a glutathione synthesis inhibitor, and 
then the responsibility of ZP-AG to renal toxicity was investigated. The mouse model showed 
significant increase in blood urea nitrogen (BUN) and creatinine (CRE), but not increase in 
alanine aminotransferase. It was demonstrated that the ZP-AG levels were elevated by 
co-treated with TOTP in the plasma and liver and especially in the kidney. The ZP-AG 
concentrations in kidney were correlated with BUN and CRE in mice receiving inhibitors and 
those not receiving inhibitors. In histopathological examination, the vacuoles and infiltration 
of mononuclear cells were observed in model mouse as described above. In addition to 
immune- and inflammation-related responses, the oxidative stress markers such as 
glutathione/disulfide glutathione ratio and malondialdehyde (MDA) levels were changed by 
TOTP, BSO and ZP-administration. Since the ZP-induced kidney injury was suppressed by 
treatment with tempol, an antioxidant agent, the involvement of oxidative stress was suggested 
in the ZP-induced kidney injury. This is the first study to demonstrate that AG accumulation in 
the kidney by TOTP and BSO-treatment would be a reason of the renal toxicity, and to show 
the in vivo toxicological potential of AGs. 
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INTRODUCTION 
 
Zomepirac (ZP), a nonsteroidal anti-inflammatory drug, was withdrawn from the market 
because of their adverse effects such as anaphylaxis and renal toxicity (Smith, 1982; Miller et 
al., 1983; Heintz, 1995). ZP is mainly metabolized to acyl glucuronide (ZP-AG) in human 
(Grindel et al., 1980; O'Neill et al., 1982). ZP-AG is more physicochemically unstable in 
phosphate buffer than the other AGs of safe drugs such as gemfibrozil, repaglunide and 
telmisartan (Sawamura et al., 2010). ZP-AG also covalently modifies dipeptidyl peptidase IV 
in rat liver homogenates and microtubular protein in bovine brain in vitro (Bailey et al., 1998; 
Wang et al., 2001). In Chapter 2, it was demonstrated that ZP-AG showed the highest 
induction of the mRNA expression immune- and inflammation-related genes in hPBMCs in 
the AGs of 13 drugs. Although the toxicity of ZP-AG has been suggested, there is no evidence 
that ZP-AG is involved in ZP-induced toxicity in vivo in both human and laboratory animals 
because of the difficulty of the toxicological assessment under the conditions sufficiently 
exposed to ZP-AG in vivo. 
The production level of AG is determined by glucuronidation catalyzed by UGT and 
enzymatic hydrolysis. The enzymatic hydrolysis of AG is catalyzed by esterases such as 
acylpeptide hydrolase and α/β hydrolase domain containing 10 (Suzuki et al., 2010; Iwamura 
et al., 2012). It was reported that the plasma clearance of ZP-AG in guinea pig was decreased 
by phenylmethylsulfonyl fluoride, a general esterase inhibitor, suggesting that ZP-AG is 
hydrolyzed by esterases (Smith et al., 1990). In other reports, esterases were potently inhibited 
by TOTP, a non-selective esterase inhibitor, in mice and rats in vivo (Silver and Murphy, 1981; 
Kobayashi et al., 2012). Beside, ZP-AG was known to be conjugated with GSH in rat 
hepatocytes and bile (Grillo and Hua, 2003). Collectively, the ZP-AG level would be regulated 
via hydrolysis by esterases and GSH conjugation against the generation by UGT. It is assumed 
that the increased exposure to ZP-AG in vivo by TOTP and BSO after ZP administration may 
show that ZP-AG rather than ZP is involved in ZP-induced toxicity in vivo. The purpose of the 
present study was to establish the ZP-induced kidney injury mouse model and to investigate 
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Chemicals and reagents  
 Reduced GSH, oxidized GSH and BSO were purchased from Wako Pure Chemical 
Industries. Zomepirac sodium and 4-hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl (tempol) 
was obtained from Sigma-Aldrich. ZP-AG and TOTP was purchased from Toronto Research 
Chemicals and Acros Organics (Morris Plains, NJ), respectively. β-NADPH and GSH 
reductase were obtained from Oriental Yeast (Tokyo, Japan). A ReverTra Ace qPCR RT kit 
was obtained from Toyobo (Osaka, Japan). RNAiso Plus and SYBR Premix ExTaq (Tli 
RNaseH Plus) were obtained from Takara (Otsu, Japan). All primers were commercially 
synthesized at Hokkaido System Sciences (Sapporo, Japan). Fuji DRI-CHEM slides of 
GPT/ALT-PIII, BUN-PIII and CRE-PIII, which were used to measure ALT, blood urea 
nitrogen (BUN) and creatinine (CRE), respectively, were from Fujifilm (Tokyo, Japan). Rabbit 
polyclonal antibody against myeloperoxidase (MPO) was purchased from DAKO (Carpinteria, 
CA). A Thiobarbituric Acid Reactive Substances (TBARS) Assay kit was obtained from 
Oxford Biomedical Research (Oxford, MI). Other chemicals used in this study were of 
analytical grade or were the highest grade commercially available. 
 
Animals 
Nine- to eleven-week-old female BALB/cCrSlc mice were obtained from Japan SLC 
(Hamamatsu, Japan). The animals were housed under a 12-hlight/dark cycle (lights on 9:00–
21:00 h) in a controlled environment (temperature 23 ± 2°C and humidity 55 ± 10%) in the 
institutional animal facility. All animals were allowed free access to food and water, except 
when fasting was being conducted. The animals were acclimatized before use in the 
experiments. All procedures were carried out in accordance with the guidelines established by 
the Institute for Laboratory Animal Research of the Medical School of Nagoya University. 
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Administration of ZP, TOTP and BSO  
ZP was dissolved in KPB (pH 7.4, 5-15 mg/mL) and intraperitoneally administered to the 
mice at a dose of 50-150 mg/kg. TOTP was dissolved in corn oil (10 mg/mL) and orally 
administered at a dose of 50 mg/kg to mice 12 h before the ZP administration. BSO was 
dissolved in saline (70 mg/mL) and intraperitoneally administered at a dose of 700 mg/kg to 
mice 1 h before the ZP administration after overnight fasting. The BSO dosage was decided to 
be 700 mg/kg because this dose has previously decreased GSH level in liver (Shimizu et al., 
2009). 
 
Administration of antioxidant agent  
Mice were intraperitoneally administered tempol, an antioxidant agent (200 mg/kg in 
sterilized PBS) at 6 h and 18 h after ZP administration. The plasma was collected at 12 h and 
24 h after ZP administration. 
 
ZP and ZP-AG Concentrations in plasma, liver and kidney  
Livers and kidneys were homogenized with homogenate buffer consisted of 10 mM 
Tris-HCl (pH 7.4), 20% glycerol, 1 mM EDTA (pH 8.0). Plasma and tissue concentrations of 
ZP and ZP-AG were determined by high-performance liquid chromatography (HPLC). Briefly, 
5 µL of plasma or 1.25 mg of tissue homogenates were mixed with 20 µL acetonitrile and 35 
µL of 8% HClO4 to precipitate the protein. The mixture was centrifuged at 13,000 g for 5 min, 
and a 40-µL sample of the supernatant was subjected to HPLC. The HPLC analysis was 
performed using an L-2130 pump (Hitachi), an L-2200 autosampler (Hitachi), an L-2400 UV 
detector (Hitachi) equipped with a Mightysil RP-18 C18 GP column (5 µm particle size, 4.6 
mm i.d. x 150 mm: Kanto Chemical, Tokyo, Japan). The eluent was monitored at 313 nm. 
Mobile phases were 47% methanol/10 mM acetate buffer (pH 5.0). The quantification of ZP 
and ZP-AG was performed by comparing the peak areas with those of authentic standards. 
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Histopathological examination  
Kidney samples were fixed in 10% neutral-buffered formalin. The fixed samples were 
dehydrated with alcohols and embedded in paraffin. Serial sections were stained with 
hematoxylin-eosin (H&E) for histopathological examination. Neutrophil infiltration was 
assessed by MPO immunostaining. A rabbit polyclonal antibody against MPO was used for 
kidney immunohistochemical staining as previously described (Kumada et al., 2004). Two 
visual fields at a 200-fold magnification (0.2 mm2 each) were randomly selected from each 
MPO-immunostained specimen. The average number of MPO-positive cells from two 
randomly selected visual fields was compared among the specimens. 
 
Real-time RT-PCR 
RNA was isolated from livers and kidneys using RNAiso Plus according to the 
manufacturer’s instructions. The mRNA expression of IL-1α, IL-6, macrophage inflammatory 
protein-2 (MIP-2/CXCL2), intercellular adhesion molecule-1 (ICAM-1/CD54), S100 
calcium-binding protein A9 (S100A9), heme oxygenase 1 (HO-1) were quantified using 
real-time RT-PCR. RT was performed using a ReverTra Ace qRT-PCR kit, according to the 
manufacturer’s instructions. In brief, 1 µg of total RNA was mixed with an appropriate volume 
of five-fold RT buffer, enzyme mix, primer mix, and nuclease-free water to adjust the total 
volume to 20 µl, and the RT reaction was carried out at 37°C for 15 min and 98°C for 5 min. 
Real-time RT-PCR was performed using a Mx3000P (Agilent Technologies, Santa Clara, CA), 
and the PCR conditions included denaturation at 95°C for 30 s, followed by 40 amplification 
cycles of 95°C for 5 s and 60°C for all of targets. The amplified products were monitored 
directly by measuring the increase in the intensity of the SYBR Green I dye binding to the 
double-stranded DNA amplified by PCR, and a dissociation curve analysis was conducted to 
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Table 8.  Sequences of primers used for real-time RT-PCR analyses. 
 
GSH levels in kidney and liver 
 Livers and kidneys were homogenized with ice-cold 5% sulfosalicylic acid and 
centrifuged at 8,000 g for 10 min at 4°C. The supernatant was collected, and the total GSH and 
disulfide glutathione (GSSG) concentrations were measured as previously described (Tietze, 
1969; Griffith, 1980). The reduced GSH contents were calculated from the total GSH and the 
GSSG contents. 
 
Malondialdehyde (MDA) levels in kidney and liver 
Livers and kidneys were homogenized with homogenate buffer. A half volume of 
trichloroacetic acid (1 g/mL) was added to tissue homogenates to precipitate proteins and 
acidify the samples, and centrifuged at 12,000 g for 5 min at 4°C. The supernatant was 
collected, and the MDA concentrations were measured using a TBARS Assay kit (Oxford 
Biomedical Research) according to the manufacturer’s protocol. The TBARS was detected by 
fluorescence (excitation 532 nm, emission 585 nm) using a PowerScan4 (DS Pharma 
Biomedical, Osaka, Japan). 
 
Genes   Primer sequences NCBI accession No. 
IL-1α S 5'- TTACAGTGAAAACGAAGAC -3' NM_010554.4 
 AS 5'- GATCTGTGCAAGTCTCATGAAG -3'  
IL-6 S 5'- CCATAGCTACCTGGAGTACA -3' NM_031168.1 
 AS 5'- GGAAATTGGGGTAGGAAGGA -3'  
MIP-2 S 5'- AAGTTTGCCTTGACCCTGAAG -3' NM_009140.2 
 AS 5'- ATCAGGTACGATCCAGGCTTC -3'  
ICAM-1 S 5'- GCTACCATCACCGTGTATTCG -3' NM_010493.2 
 AS 5'- TGAGGTCCTTGCCTACTTGC -3'  
S100A9 S 5'- GATGGCCAACAAAGCACCTT -3' NM_009114.3 
 AS 5'- CCTCAAAGCTCAGCTGATTG -3'  
HO-1 S 5'- GACACCTGAGGTCAAGCACA -3' NM_010442.2 
  AS 5'- ATCACCTGCAGCTCCTCAAA -3'   
S, Sense; AS, Anti-sense. 
IL, interleukin; MIP-2, macrophage inflammatory protein-2; ICAM-1, intercellular adhesion molecule-1; S100A9, S100 
calcium-binding protein A9; HO-1, heme oxygenase 1. 
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Statistical analysis  
The statistical analysis of multiple groups was performed using Dunnett’s test or Tukey’s 
test to determine the significance of differences between individual groups. Comparisons 
between two groups were carried out using two-tailed Student’s t-tests. A value of P < 0.05 




Establishment of the ZP-induced kidney injury mouse model  
In female BALB/c mice administrated with ZP (150 mg/kg, i.p.), the plasma levels of 
CRE, BUN and ALT were not increased at 24 h after the administration (Fig. 8). Considering 
the possibility that GSH conjugation and hydrolysis of ZP-AG might be involved in 
ZP-induced toxicity, the effects of co-treatment with BSO or TOTP, a GSH synthesis inhibitor 
(Shimizu et al., 2009) or an esterase inhibitor (Emeigh Hart et al., 1991), respectively, were 
investigated. Co-administration of BSO resulted in slight increase in CRE and BUN compared 
with the group administered with ZP alone. Whereas, CRE and BUN were significantly 
elevated by co-administration of TOTP, although ALT was not affected. The highest increases 
in CRE and BUN were observed in mice co-administrated with both TOTP and BSO. No 
increase in plasma CRE, BUN and ALT levels in mice receiving TOTP or BSO only was 
confirmed. These results suggest that the inhibition of GSH conjugation and hydrolysis of 
ZP-AG contributes to the kidney injury caused by ZP administration.  
 
  















Fig. 8. Changes in plasma CRE (A), BUN (B) and ALT (C) levels in female BALB/c mice after ZP 
administration. TOTP (50 mg/kg in corn oil, p.o.), BSO (700 mg/kg in saline, i.p.) and ZP (150 mg/kg in KPB, 
i.p.) were administered as described in Experimental Procedures. The plasma CRE, BUN and ALT levels were 
measured 24 h after ZP administration. The data are shown as the mean ± SEM (n = 5-7). The statistical analyses 
were performed using one-way ANOVA followed by Dunnett’s test. **P < 0.01 compared with the vehicles (corn 
oil, saline and KPB) alone-treated group. #P < 0.05, ##P < 0.01 compared with the ZP alone-treated group. 
 
Dose- and time-dependent changes of ZP-induced kidney injury  
ZP was administered at a dose of 50, 100, or 150 mg/kg with co-administration of TOTP 
and BSO to mice. Plasma CRE and BUN levels were significantly and dose-dependently 
increased in mice receiving 100 and 150 mg/kg of ZP compared with vehicle 
(KPB)-administered control mice; thus for subsequent experiments we adapted a dose of ZP at 
150 mg/kg (Fig. 9). As shown in Figs. 10A-10C, plasma CRE and BUN levels were 
time-dependently increased 12 and 24 h after ZP-administration, but plasma ALT levels did 
not. 
 






















Fig. 9. Dose-dependent changes in plasma CRE (A), BUN (B) and ALT (C) levels after ZP administration in 
mice. TOTP and BSO were administered as described in Experimental Procedures. ZP was administered at a dose 
of 50, 100 and 150 mg/kg. The plasma CRE, BUN and ALT levels were measured 24 h after ZP administration. 
The data are shown as the mean ± SEM (n = 5-7). Differences compared with the inhibitors alone-treated group 
were considered significant at *P < 0.05, **P < 0.01 by one-way ANOVA followed by Dunnett’s test. 
 
Time-dependent changes of ZP and ZP-AG concentrations in plasma, kidney and liver  
The concentrations of ZP and ZP-AG in plasma, kidney and liver were measured in mice 
after ZP administration with or without co-administration of TOTP and BSO. In plasma, 
kidney and liver, the concentrations of ZP were significantly lower in mice receiving TOTP, 
BSO and ZP compared with those in mice receiving ZP alone (Fig. 10D). Whereas, the plasma 
and the tissue concentrations of ZP-AG were significantly higher in mice receiving TOTP, 
BSO and ZP compared with those in mice receiving ZP alone (Fig. 10E). In groups 
co-administered with or without the inhibitors, the ZP concentrations in the kidney were 
almost the same as those in the liver, whereas the ZP-AG concentrations in the kidney were 
much higher than those in the liver. These results imply that the ZP-AG would slowly be 
eliminated from the kidney, resulting in high accumulation in the kidney. 















Fig. 10. Time-dependent changes in plasma CRE (A), BUN (B), ALT (C) levels and concentrations of ZP 
(D) and ZP-AG (E) in plasma, kidney and liver after ZP administration. TOTP, BSO and ZP were 
administered as described in Experimental Procedures. The plasma CRE, BUN and ALT levels were measured 3, 
6, 12 and 24 h after ZP administration. Concentrations of ZP and ZP-AG in plasma, kidney and liver were 
measured 0.5, 1, 3, 6, 12 and 24 h after ZP administration. The data are shown as the mean ± SEM (n = 5-7). 
Differences in plasma CRE, BUN and ALT levels compared with the ZP alone-treated group were considered 
significant at *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t-tests. Differences in the concentrations of ZP 
and ZP-AG in plasma, kidney and liver compared with the ZP alone-treated group were considered significant at 
#P < 0.05 by Student’s t-tests. 
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Histopathological examination in ZP-induced kidney injury 
To evaluate the tissue injury, histopathological examination of kidney 24 h after ZP 
administration (150 mg/kg) was performed. Vacuoles, the denaturation and aggregation of 
eosinophilic materials were observed in the kidney of mice co-administrated with ZP and 
inhibitors, although the histological abnormality was mild in mice receiving only ZP, and no 
abnormality was observed in mice receiving vehicles or only inhibitors (Fig. 11A). In the 
anti-MPO antibody staining, the number of MPO-positive cells was significantly higher in 
mice receiving TOTP, BSO and ZP compared to mice receiving only ZP. In contrast, 
infiltration of mononuclear cells into the renal cells was not observed in mice receiving 















Fig. 11. Histopathological examination of mouse kidney after ZP administration. TOTP, BSO and ZP were 
administered as described in Experimental Procedures. The kidneys were collected at 24 h after ZP 
administration, and the kidney sections were stained with hematoxylin and eosin (H&E) (A) or immunostained 
with an anti-myeloperoxidase (MPO) antibody (B). Arrowheads indicate immune cell infiltration. The number of 
MPO-positive cells was counted and compared with the ZP alone-treated group (C). The data are shown as the 
mean ± SEM (n = 5-7). The difference compared between the ZP alone-treated group and ZP and 
inhibitors-treated group was considered significant at *P < 0.05 by Student’s t-tests. 
A
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Changes in mRNA expression levels of immune-, inflammation- and oxidative stress-related 
genes in kidney  
To investigate whether immune-, inflammation- and oxidative stress-related factors are 
involved in ZP-induced kidney injury, time-dependent changes in the renal mRNA expression 
levels of IL-1α, IL-6, MIP-2, ICAM-1, S100A9 and HO-1 were measured (Fig. 12). IL-1α 
mRNA expression levels in only ZP-receiving mice were significantly increased 12 h after ZP 
administration, and those in TOTP, BSO and ZP-receiving mice were additionally increased 
not only 12 h but also 1 h after ZP administration. IL-6 and ICAM-1 mRNA expression levels 
in mice receiving TOTP, BSO and ZP were significantly increased in mice receiving TOTP, 
BSO and ZP 1 h and 12 h after ZP administration, in contrast to small increase in mice 
receiving only ZP. S100A9 mRNA expression levels in only ZP-receiving mice were 
significantly increased 1 h after ZP administration, but those in TOTP, BSO and ZP-receiving 
mice were significantly increased 12 h and 24 h after ZP administration. Only in mice 
receiving TOTP, BSO and ZP, the mRNA expression levels of HO-1 were significantly 
increased 12 h and 24 h after ZP administration. Although the mRNA expression levels of 
transcription factors for the Th lineage in adaptive immunity, such as T-box expressed in T 
cells, GATA-binding domain-3 retinoid-related orphan receptor-γt and forkhead box P3, no 
change was observed in their expressions between any groups (data not shown). 
  






















Fig. 12. Time-dependent changes in the renal mRNA expression levels of immune-, inflammation- and 
oxidative stress-related genes in mice after ZP administration. TOTP, BSO and ZP were administered as 
described in Experimental Procedures. The kidneys were collected at 1, 12 and 24 h after ZP administration. The 
expression level of each mRNA was measured by real-time RT-PCR and normalized with that of Gapdh mRNA 
as described in Experimental Procedures. The data are shown as the mean ± SEM (n = 5-6). The statistical 
analyses were performed using one-way ANOVA followed by Tukey’s test. *P < 0.05, **P < 0.01, ***P < 0.001, 
compared with the inhibitors alone-treated group. #P < 0.05, ##P < 0.01, ###P < 0.001, compared with the ZP 
alone-treated group. 
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Involvement of oxidative stress in ZP-induced kidney injury  
To conform the depletion of GSH by BSO treatment and to investigate the involvement of 
oxidative stress in ZP-induced kidney injury, GSH and GSSG contents in kidney and liver 
were measured (Figs. 13A-13C). In the kidney, GSH depletion by BSO was conformed in 
mice treated with TOTP and BSO. In addition, GSH levels in mice receiving TOTP, BSO and 
ZP were significantly lower compared with those in mice receiving only inhibitors. Owing to 
the decrease of GSH levels, GSH/GSSG ratio, a biomarker of oxidative stress, was 
significantly lower in BSO, TOTP and ZP-treated mice compared with BSO and TOTP-treated 
mice. In liver, GSH was depleted by BSO, but GSH/GSSH ratio was not different between 
TOTP and BSO-treated group and TOTP, BSO and ZP-treated groups.  
In addition, MDA concentrations, a biomarker of lipid peroxidation, were measured in the 
kidney and liver (Fig. 13D). In the kidney, MDA concentrations were significantly higher in 
TOTP, BSO and ZP-treated mice compared with TOTP and BSO-treated mice, but in the liver, 
there was no change in MDA concentrations between these groups. 
 
Effect of an antioxidant agent on ZP-induced kidney injury 
The changes of oxidative stress markers implied the involvement of oxidative stress in 
ZP-induced kidney injury. Next, the effect of tempol, an antioxidant agent, on ZP-induced 
kidney injury was investigated. The co-administration of tempol significantly decreased the 
plasma CRE levels at 12 h and BUN levels at 12 and 24 h after ZP administration in BSO, 
TOTP and ZP-treated mice (Fig. 14). These results also support the involvement of oxidative 
stress in ZP-induced kidney injury. 
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Fig. 13. The GSH (A) and GSSG (B) levels, 
GSH/GSSG ratio (C) and MDA levels (D) in 
kidney and liver after ZP administration. 
TOTP, BSO and ZP were administered as 
described in Experimental Procedures. The 
kidney and liver were collected at 12 h after ZP 
administration. The data are shown as the mean 
± SEM (n = 5-6). The difference compared 
between the inhibitors alone-treated group and 
ZP and inhibitors-treated group was considered 
significant at **P < 0.01, ***P < 0.001 by 
Student’s t-tests. 
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Fig. 14. Effect of an antioxidant agent on kidney injury of 
ZP-administered mice. TOTP, BSO, ZP and tempol were 
administered as described in Experimental Procedures. The plasma 
CRE (A) and BUN (B) levels were measured 12 and 24 h after ZP 
administration. The data are shown as the mean ± SEM (n = 6). 
Differences compared with no tempol-treated group were considered 
significant at *P < 0.05, ***P < 0.001 by Student’s t-tests. 
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DISCUSSION 
 
AGs of drugs are generally unstable and are believed to be involved in drug-induced 
toxicity via the formation of covalent adducts to endogenous proteins. Although there is 
increasing evidence that AGs form drug-protein adducts owing to their chemical reactivity 
(Wang et al., 2001; Horng and Benet, 2013), cytotoxicity and genotoxicity of AGs have not 
been observed in in vitro assays (Koga et al., 2011). In the previous report and Chapter 2, the 
AGs of warning and withdrawn drugs such as zomepirac and diclofenac induced the mRNA 
expression levels of immune- and inflammation-related genes in hPBMCs (Miyashita et al., 
2014). Thus, the toxicity of AGs evaluated by in vitro studies remains controversial. 
ZP is a nonsteroidal anti-inflammatory drug that is withdrawn from the market because of 
severe adverse effects such as anaphylaxis and renal toxicity (Smith, 1982; Miller et al., 1983; 
Heintz, 1995). It has been shown that ZP-AG, a glucuronide of ZP, covalently bound proteins 
such as microtubular protein and dipeptidyl peptidase IV in in vitro and in vivo experiment, 
suggesting the involvement of ZP-AG in ZP-induced toxicity (Bailey et al., 1998; Wang et al., 
2001). However, an animal model for the toxicity induced by ZP-AG has never been reported. 
In order to establish a mouse model of the toxicity induced by ZP-AG, we attempted to 
increase the exposure of ZP-AG in mice by inhibiting its hydrolysis by using an inhibitor of 
esterases. A previous study reported that ZP-AG is hydrolyzed by esterases (Smith et al., 
1990). TOTP, a non-selective esterase inhibitor, successfully inhibited esterase activity in mice 
and rats in vivo (Silver and Murphy, 1981; Kobayashi et al., 2012). In the present study, in 
addition to TOTP, BSO was used to reduce the GSH conjugation of ZP-AG. 
The renal and hepatic toxicity was not observed by administration of only ZP. 
Co-administration of TOTP significantly increased the plasma CRE and BUN levels and that 
of BSO moderately increased them. Co-administration of TOTP and BSO with ZP showed the 
severest renal toxicity, suggesting that hydrolysis and GSH conjugation of ZP-AG have a role 
for detoxification of ZP-AG. In contrast to plasma CRE and BUN levels, plasma ALT levels 
were not elevated in any groups, which corresponds to the facts that acute kidney injury was 
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frequently reported in ZP therapy in human. The present study succeeded to establish an 
animal model of ZP-induced kidney injury by co-administration of TOTP and BSO. 
To examine the relationship between the extent of kidney injury and the exposure of ZP 
and ZP-AG, the concentrations of ZP and ZP-AG in the plasma, kidney and liver were 
measured. ZP-AG concentrations in plasma, kidney and liver were significantly higher in mice 
receiving TOTP, BSO and ZP compared with in mice receiving ZP alone. Especially high 
concentration of ZP-AG was observed in the kidney, suggesting ZP-AG had potential to lead 
to kidney injury. ZP-AG concentrations in the liver were much lower than those in the kidney, 
although the ZP concentrations in the liver were almost the same as those in the kidney. These 
results indicated that ZP-AG was more toxic than ZP, because no hepatotoxicity was observed 
after ZP dosing. ZP and its metabolites are primarily excreted into urine, and urinary principal 
metabolite is ZP-AG in both mouse and human, whereas the urinary excretion ratio of ZP-AG 
in human is higher than that in mouse (57% and 19-28% of dose, respectively) (Grindel et al., 
1980). Therefore, the exposure level of ZP-AG in the present model mouse receiving 
inhibitors, rather than normal mouse, would be close to that in human, suggesting that this 
model might be used to predict the toxicity caused by ZP-AG in human. 
In general, glucuronides in hepatocytes are eliminated into bile and blood by 
multidrug-resistance protein (Mrp) 2 and Mrp 3, respectively (Trauner and Boyer, 2003). It has 
been demonstrated that, in human hepatocytes, the AGs of NSAIDs (diclofenac, naproxen, 
ketoprofen and ibuprofen) were rapidly excreted and did not accumulate in the cell (Koga et 
al., 2011). ZP-AG would be immediately exported from liver into blood rather than bile, 
because excretion of ZP and its metabolites into bile is a minor route in human and laboratory 
animals (Grindel et al., 1980). Thus, these reports support the finding that ZP-AG accumulated 
in the kidney, but not in the liver.  
In histopathological examination, the present mouse model of ZP-induced kidney injury 
displayed vacuoles and denatured cytoplasm and aggregated eosinophilic materials, probably 
reflecting cellular necrosis. In the ZP-induced kidney injury in clinical, renal cortical necrosis 
was observed (Darwish et al., 1984), and the results observed in the present study was 
  48 
consistent with the clinical findings. In preclinical studies, almost all of the NSAIDs produced 
papillary necrosis in experimental animal models (Whelton and Hamilton, 1991). The possible 
mechanism of papillary necrosis is ischemic injury through the direct inhibition of 
cyclooxygenase-mediated production of prostaglandins (Brix, 2002). However, the inhibition 
of cyclooxygenase by ZP might not contribute to ZP-induced kidney injury because papillary 
necrosis was not observed in this injury. The increased number of MPO-positive cells 
suggested the contribution of immune cell infiltration to ZP-induced kidney injury. 
From the results in Chapter 2, AGs of warning and withdrawn drugs induced immune- and 
inflammation-related genes such as IL-1α and IL-6 in hPBMCs. Hence, the changes in the 
renal mRNA expression levels of immune- and inflammation-related genes were measured. 
The mRNA expressions of IL-1α and IL-6 were induced in the mice highly exposed to ZP-AG, 
and followed by ICAM-1 and S100A9 mRNAs. IL-1α, a trigger of cascades of chemokines, 
other cytokines and inflammatory mediators, is synthesized in the first few hours in the 
injurious or ischemic event (Dinarello et al., 2012). IL-6 is also rapidly induced as a 
lymphocyte-stimulating factor and leads to innate and adaptive immune activation (Hunter and 
Jones, 2015). ICAM-1, an adhesion molecule, is involved in infiltration of inflammatory cells 
(Ley et al., 2007). S100A9, damage-associated molecular patterns, is released from activated 
or necrotic neutrophils and monocytes/macrophages and promotes innate immune and 
inflammation (Schiopu and Cotoi, 2013). The stimulation of IL-1α induces ICAM-1 and 
S100A9 (Aziz and Wakefield, 1996; Zreiqat et al., 2010), and so does IL-6 (Wung et al., 2005; 
Lee et al., 2012). Because the injection of recombinant IL-1α accelerates renal injury and 
mortality in mice (Brennan et al., 1989), and IL-6- or ICAM-1-deficient mice show protective 
effect against acute kidney injury, these factors could trigger and promote the kidney injury 
(Kelly et al., 1996; Nechemia-Arbely et al., 2008). Taken together, it was conceivable that 
IL-1α and IL-6 induced by ZP-AG at the onset promoted the infiltration of immune cells via 
the induction of ICAM-1 and MIP-2, and then the infiltrating cells caused kidney injury. 
Of particular note was the potent induction of HO-1 mRNA in mice co-administered with 
TOTP and BSO, suggesting that ZP-AG was involved in ZP-induced kidney injury via the 
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induction of oxidative stress. The decrease in GSH/GSSG ratio and the increase in MDA 
concentrations were observed in the kidney, but not in the iver, being consistent with each 
tissue injury. Partial involvement of oxidative stress was also demonstrated by experiments 
using tempol. In accordance with the results of the GSH/GSSG ratio and the MDA 
concentrations, an antioxidant tempol suppressed ZP-induced kidney injury, suggesting that 
oxidative stress was involved in the renal toxicity. It was reported that the decrease in the 
GSH/GSSG ratio and the increase in the MDA concentrations were observed in 
cisplatin-induced acute renal failure in rats (Santos et al., 2007). Tempol attenuated oxidative 
stress-mediated renal injury in rats (Chatterjee et al., 2000). These results were close to the 
results observed in the present study.  
In conclusion, a mouse model for ZP-induced kidney injury was established by using 
TOTP and BSO in consideration of the metabolic pathway of ZP. From the pharmacokinetics 
of ZP and ZP-AG, it was shown that the hydrolysis of ZP-AG by esterases considerably 
contributed to their pharmacokinetics and ZP-AG would be responsible for ZP-induced kidney 
injury in vivo. In addition, it was demonstrated that the renal toxicity was mediated via 
oxidative stress and immune cells infiltration. The model using TOTP can be used to evaluate 
the toxicity of AGs in preclinical, and the present study sheds light on understanding the 
toxicological potential of AGs. 
	 





Highlights in the present study were described as follow. 
・	 Immunostimulation assay using 5 gene expressions in hPBMC as biomarkers showed 
high accuracy. 
・	 ZP-AG is responsible for ZP-induced kidney injury in vivo. 
・	 The evaluation of AG toxicity can contribute to improve the risk assessment in drug 
development. 
 
AGs covalently bind to endogenous proteins owing to their instability, and have been 
believed to be related with the toxicity of carboxyl acid drugs. However, the theory remains 
controversial. The purpose of this study was to evaluate the toxicological potential of AGs by 
in vitro and in vivo experiments.  
To investigate direct and immune-mediated toxicity by AGs as possible mechanisms of 
toxicity, in Chapter 2, the assays of half-lives, peptide adducts and immunostimulation of 
AGs of 21 drugs were performed, and then the relationship to the toxic category was analyzed. 
In half-lives and peptide adducts assays, the AGs of withdrawn drugs had short half-lives and 
formed glycation adducts, but the AGs of several safe drugs also did. The results indicated that 
these assays have potential for the false-positive prediction.  The stimulation of 
immune-related factors by AGs was investigated using hPBMCs. The induction of IL-8 
mRNA expression by AGs of withdrawn and warning drugs was observed, while that by AGs 
of safe drugs was not.  DNA microarray analysis was performed to search other biomarkers for 
toxicity of AGs. As the results, in addition to IL-8, 4 genes (IL-1α, IL-6, MT2A, and NAMPT) 
were found, and an integrated score of the relative expression levels of mRNA of these 5 genes 
in hPBMCs could successfully distinguish the withdrawn and warning drugs from safe drugs. 
The immunostimulation assay showed the highest accuracy among three assays tested in this 
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study, although this assay requires authentic AG standards. In preclinical stage in drug 
development, the evaluation of immunostimulation by AGs using hPBMCs can contribute to 
improved drug safety. 
ZP was withdrawn from the market due to adverse effects such as renal toxicity and 
anaphylaxis. It was demonstrated by previous studies that ZP-AG formed protein adducts and 
the study in Chapter 2 revealed that ZP-AG had the highest total sum score among the tested 
AGs. However, the toxicity of ZP-AG has not been proved by in vivo study. In Chapter 3, it 
was investigated by in vivo study whether ZP-AG is responsible for renal toxicity by ZP. No 
renal toxicity was observed by administration of only ZP, whereas the severe renal toxicity 
was observed by co-administration of TOTP and BSO with ZP. Co-administration with TOTP 
and BSO increased concentrations of ZP-AG in plasma and liver, especially in kidney, 
suggesting that ZP-AG leads to renal toxicity. In the mouse model of ZP-induced kidney 
injury, MPO-positive cells infiltrated into the renal cells; hence, the mRNA expression levels 
of immune- and inflammation-related genes were measured.  In addition to ICAM-1 that is 
involved in immune cell infiltration, IL-1α, IL-6 and S100A9 mRNA expression were induced 
in the mouse model. The mRNA expression levels of HO-1, an oxidative stress-related gene, 
were also increased. In accordance with these results, GSH/GSSG ratio was decreased and 
MDA level was increased in kidney. In addition, an antioxidant agent, tempol attenuated 
ZP-induced kidney injury. The mouse model established in the present study is expected to be 
used for evaluating the in vivo toxicity of AGs in preclinical stage in drug development. 
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